Effects Of Fish Oil Emulsion On Severe Acute Pancreatitis Patients

Phase 2

Completed

• Conditions: Assess Effect of Omega-3 Fish Oil in Patients With Severe Acute Pancreatitis
• Interventions: Dietary Supplement: Lipofundin® MCT/LCT 20%; Dietary Supplement: Lipidem (Omega-3 fish oil lipid emulsion)

• Registration Number: NCT01745861
• Lead Sponsor: University Hospitals, Leicester

Brief Summary

The incidence of acute pancreatitis in UK has risen sharply over the past 40 years. Recent reports suggest that 56.5 per 100 000 of the population will suffer from AP annually; this figure is more than double the highest previous estimated incidence. In the majority of patients the condition is mild, but about 25% of patients suffer a severe attack and between 30 and 50% of these patients dies. The usual cause of death is multiple organ failure secondary to systemic leukocyte activation (mainly neutrophils), accompanied by the systemic inflammatory response syndrome (SIRS).

Studies with omega-3 fish oil have shown to control inflammatory process and improve the outcome especially in hyperinflammatory conditions.

This research will look at the effects of supplementing omega-3 fish oil to patients with severe acute pancreatitis (severe inflammation of the pancreas).

Patients with severe acute pancreatitis will be prospectively and blindly randomised into either a study group who will receive (Lipidem, lipid emulsion contains essential fatty acids and omega-3 fish oil) or a control group that will receive (Lipofundin, lipid emulsion contains only essential fatty acids and no omega-3 fish oil). Normal and standard clinical care will be provided to all patients as per the national management guidelines. Each patient will receive either Lipidem or Lipofundin emulsions daily until they are deemed fit for discharge by their own medical team or for a maximum of SEVEN days.

The main aim of this study is to examine whether lipid emulsions enriched with omega-3 fish oil could improve the clinical outcome in patients with severe acute pancreatitis.

Detailed Description

This research project is designed to give lipid emulsion enriched with omega-3 fish oil to conscious adult patients with mental capacity to consent for themselves and with severe acute pancreatitis in Leicester General Hospital wards or units.

Potential participants with SAP will be identified by the patient's own team and referred to the researchers for consideration and eventual enrolling in the study. Unconscious patients or unable to consent for themselves will be EXCLUDED from the study.

Randomization:

Patients will be randomised to receive Lipidem 200 mg/ml OR Lipofundin MCT/LCT 20% lipid emulsion from random number tables. Randomization, blinding procedure (over labeling) will be conducted by an independent licensed pharmaceutical unit.

Study Timeline

• Study Start: 2010-06
• Primary Completion: 2012-02
• Study Completion: 2012-02
• Study First Submitted: 2012-11-13
• Status Verified: 2012-12
• Study First Submitted QC: 2012-12-07
• Last Update Submitted: 2012-12-07
• Study First Posted: 2012-12-10
• Last Update Posted: 2012-12-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 44

Inclusion Criteria

Conscious patients between age of 18-90 admitted to the Leicester General hospital with severe acute pancreatitis proven by:

1. compatible clinical features (abdominal pain with or without vomiting);
2. associated with elevated serum amylase levels (≥3 normal value) (≥300 iu/l);
3. one or more of the severity criteria as outlined in the Atlanta severity criteria or modified glasgow acute pancreatitis severity score ≥3

Exclusion Criteria

• Patients unconscious or unable to consent.
• Patients under 18 years old or above 90 years old
• Hypersensitivity to fish, egg or soy protein or other active substances of the TPN.
• Uncontrolled hyperlipidaemia
• Severe primary blood coagulation disorder
• Acute pancreatitis accompanied with hyperlipidaemia
• Ketoacidosis
• Acute thromboembolic disease
• Severe liver failure
• Acute phase of myocardial infarction or stroke
• Pregnancy and lactation
• Severe renal failure without access to haemofiltration or dialysis

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Lipofundin® MCT/LCT 20%	Lipofundin® MCT/LCT 20%	Lipid emulsion containing medium and long chain triglycerides
Lipidem® (BBraun)	Lipidem (Omega-3 fish oil lipid emulsion)	Lipid emulsion containing medium chain triglycerides (MCT), long chain triglyceride (LCT) and Omega-3 fatty acid (fish oil)

Primary Outcome Measures

Name	Time	Method
Reduction of the CRP by 20% from the control group	Day 7 post infusion

Secondary Outcome Measures

Name	Time	Method
Escalation of care to high dependency or intensive care unit and length of hospital stay	On days 1, 2, 3, 5 and 7 post infusion
Progression in the Sequential Organ Failure Assessment (SOFA) Score	On days 1, 2, 3, 5 and 7 post infusion
Progression in the Multiple Organ Dysfunction Score (MODS)	On days 1, 2, 3, 5 and 7 post infusion
Progression in the Systemic Inflammatory Response Syndrome	On days 1, 2, 3, 5 and 7 post infusion
Progression in the inflammatory and anti-inflammatory mediators (IL-1RA, IL-10, IL-6, IL-18, TNF-a, ICAM-1, IL-10 etc...).	On days 1, 2, 3, 5 and 7 post infusion

Trial Locations

Locations (1)

Leicester General Hospital, University Hospitals of Leicester NHS Trust; 🇬🇧 Leicester, Leicestershire, United Kingdom